Introduction
The c-Rel transcription factor is a member of the Rel/ NF-kB family, which also includes RelA (p65), RelB, p50, and p52 (Gilmore, 2003) . As Rel/NF-kB transcription factors have been the subject of numerous reviews, this article will focus on the unique role of c-Rel in controlling B-cell proliferation, survival, and oncogenesis. In a variety of cell types, c-Rel exists as homodimers or heterodimers with p50, or infrequently with RelA. Dimers containing c-Rel bind to a set of related 9-10 bp DNA sequences (kB sites), and regulate the expression of numerous cellular genes, including many genes involved in lymphoid cell development, proliferation, and survival.
Rel/NF-kB proteins are related through an approximately 300-amino-acid N-terminal domain usually called the Rel homology domain, which has sequences required for DNA binding, dimerization, nuclear localization, and inhibitor (IkB) binding. Sequences C-terminal to the Rel homology domain in c-Rel, RelA, and RelB contain transcriptional activation domains, and therefore dimers that contain these Rel/NF-kB members usually increase transcription of target genes. Although the Rel homology domain sequences of c-Rel proteins across species are highly conserved, their C-terminal transactivation domains are not. For example, the Rel homology domains of chicken and human c-Rel are approximately 85% identical, whereas their C-terminal transactivation domains are only about 10% identical. Therefore, the DNA-binding specificities of c-Rel proteins across species are likely to be quite similar, but the properties and regulation of their transactivation domains may vary.
The activity of Rel/NF-kB dimers is also highly regulated. The primary method of Rel/NF-kB regulation is through interaction with the family of IkB inhibitor proteins (Ghosh and Karin, 2002) . Interaction of the Rel/NF-kB dimer with the IkB protein generally sequesters the complex in the cytoplasm and blocks its ability to bind DNA. Activation of the Rel/NF-kB pathway by any number of inducers activates an IkB kinase (IKK) complex, which then phosphorylates IkB. Phosphorylated IkB is then a preferred substrate for ubiquitination and degradation by the proteasome, which frees the Rel/NF-kB complex to enter the nucleus and bind to target gene promoters/enhancers. However, in some cases, Rel/NF-kB proteins may also have effects on gene expression that are not mediated by direct DNA binding, such as by interacting with heterologous DNAbound transcription factors. For example, NF-kB can enhance bcl-2 gene expression by associating on the bcl-2 enhancer through CREB and Sp1 (Heckman et al., 2002) .
Like other Rel/NF-kB proteins, c-Rel is also subject to regulation beyond that imposed by IkB proteins. Phosphorylation has been reported to affect c-Rel DNA binding (Neumann et al., 1992; Glineur et al., 2000; Liu and Beller, 2002) and its C-terminal transactivation activity (Martin et al., 2001) . Moreover, even though the C-terminal transactivation domains of human and chicken c-Rel are weakly, if at all, conserved (Gilmore et al., 2001) , they both contain numerous sites of serine phosphorylation Martin et al., 2001) . In the case of REL, phosphorylation of different sets of serine residues affects its transactivation activity in response to different stimuli, such as phorbol ester/ ionomycin versus tumor necrosis factor (Martin and Fresno, 2000; Martin et al., 2001) . In addition, the Cterminal domain of REL has numerous sites of ubiquitination , which has recently been shown to play a role in transactivation in other transcription factors (Jin and Harper, 2003) .
c-Rel plays a role in B-Cell proliferation and survival
The distinct phenotypes of knockout mice lacking individual Rel/NF-kB family members and the different expression patterns of these proteins indicate that each family member has unique physiological functions. As such, a role for c-Rel in B-cell development, growth, and survival has been established by the analysis of c-Rel expression and activity and by the characterization of c-rel knockout mice.
The first indication that c-Rel might have a unique role in lymphoid cells came from in situ hybridization studies of mouse embryos and adult tissues, wherein it was found that c-rel mRNA was expressed primarily in developing hematopoietic tissues . The c-Rel protein is expressed at all stages of B-cell development, but is expressed at the highest levels and is constitutively nuclear in mature B cells (Grumont and Gerondakis, 1994; Liou et al., 1994; Weih et al., 1994) . The nuclear kB site DNA-binding activity in mature B lymphocytes consists mainly of p50-c-Rel heterodimers, which is different from pre-B cells that have largely inducible p50-RelA complexes (Grumont and Gerondakis, 1994; Liou et al., 1994; Miyamoto et al., 1994b; Kistler et al., 1998) . Moreover, c-rel mRNA has recently been shown to be elevated in mature B cells as compared to plasma B cells (Tarte et al., 2003; Zhan et al., 2003) , paralleling the protein expression data.
The preferential nuclear accumulation of c-Rel in mature B cells is probably due, at least in part, to increased basal turnover of IkBa in these cells (Miyamoto et al., 1994a (Miyamoto et al., , 1998 Doerre and Corley, 1999; Shumway et al., 1999; Fields et al., 2000) . In addition, Tam et al. (2001) have shown that the nuclear accumulation of p50-c-Rel heterodimers in lieu of p50-RelA heterodimers in mature B cells can also be attributed to the types of IkB interactions that occur with the different Rel/NF-kB heterodimers and to the nuclear export rates of different heterodimers. Namely, RelA contains a nuclear export sequence whereas c-Rel does not, and therefore p50-RelA heterodimers are exported more efficiently from the nucleus than p50-cRel heterodimers. Moreover, in pre-B cells and non-B cells, c-Rel complexes are primarily associated with IkBb, which does not shuttle through the nucleus, whereas in mature B cells, a significant portion of c-Rel is also associated with IkBa, which does shuttle continuously through the nucleus. Thus, although IkBa-p50-RelA and IkBa-p50-c-Rel complexes both shuttle through the nucleus in mature B cells, the reduced nuclear export of c-Rel as compared to RelA results in increased nuclear accumulation of p50-c-Rel versus p50-RelA. All of these may be accelerated in the background of increased IkBa turnover in mature B cells.
c-rel knockout mice develop normally and have no gross irregularities in hemopoiesis, but show immunodeficiencies (Ko¨ntgen et al., 1995; Tumang et al., 1998) . Although c-rel knockout mice show some alterations in T-cell function , the primary defects in these mice occur in B cells. In particular, c-rel knockout mice have greatly reduced B-cell proliferation and reduced survival in response to mitogenic activation, such as by treatment with LPS, anti-IgM, antigen, or CD40, and show reduced antibody production in response to antigen (Ko¨ntgen et al., 1995; HarlingMcNabb et al., 1999; Tumang et al., 2002) . The reduced mitogen-induced proliferation is due to arrested cellcycle progression in c-relÀ/À B cells . However, c-Rel is not required for antigen-independent B-cell proliferation that occurs during B-cell depletion (Cabatingan et al., 2002) . Consistent with the B-cell proliferation and survival defects, c-rel null mice have small/irregular germinal centers and reduced marginal zone B cells (Cariappa et al., 2000) . Recently, Cheng et al. (2003) have shown that overexpression of both cyclin E and Bcl-X L can restore BCR-induced cell-cycle progression and survival in c-relÀ/À B cells; Bcl-X L is likely to be a direct target for c-Rel activation, whereas cyclin E gene expression is likely induced by c-Relmediated activation of cell-cycle transcription factor E2F3a.
The c-rel null phenotypes are exacerbated in nfkb1/ c-rel double knockouts, which have reduced numbers of follicular, marginal, and peritoneal B cells and have mature B cells that fail to proliferate in response to antigen due to a cell-cycle defect (Pohl et al., 2002) . Adoptive transfer studies have shown that embryonic liver cells lacking both RelA and c-Rel can still repopulate all hematopoietic cell lineages, although at a somewhat reduced level compared to wild-type cells (Grossmann et al., 1999) , emphasizing that both activating subunits of NF-kB are not required for hematopoietic cell development. However, mature IgMand IgD-positive B cells were absent in these mice, because of a survival defect as a result of reduced expression of antiapoptotic genes bcl-2 and A1 (Grossmann et al., 2000) . Indeed, expression of a bcl-2 transgene in the c-rel/rela double knockout cells can restore their ability to generate peripheral B cells in adoptive hosts (Grossmann et al., 2000) . Thus, c-Rel and RelA appear to serve essential but redundant functions in the development of mature B cells, and c-rel knockout mice have increased levels of p50-RelA in their splenic B cells, no doubt as a compensation for the lack of c-Rel (Gerondakis et al., 1996; Liou et al., 1999) .
The homozygous disruption of several non-Rel/NFkB genes has been shown to affect both c-Rel and B-cell maturation or proliferation, suggesting that these genes are involved in c-Rel expression, activity, or regulation. Surprisingly, little work has been performed on regulation of c-rel gene transcription; however, the mouse c-rel promoter has binding sites for the Ets family proteins c-Rel and B-cell proliferation/oncogenesis TD Gilmore et al PU.1 and SpiB, and has several Rel/NF-kB binding sites. Thus, c-Rel can enhance its own expression (Grumont et al., 1993) . Moreover, PU.1
,SpiB À/À mice have reduced c-rel mRNA expression and reduced numbers of immature and mature B cells (Hu et al., 2001) . Expression of an exogenous c-rel gene in PU.1
B cells restores their ability to form normal numbers of B cells in bone marrow reconstitution experiments (Hu et al., 2001) . Similarly, mice deficient in B-cell adaptor for PI3 kinase (BCAP) have reduced numbers of mature B cells due to reduced survival and proliferation, and their B cells have reduced levels of c-Rel (Yamazaki and Kurosaki, 2003) . Re-expression of c-Rel in BCAPdeficient B cells restores both the number of mature B cells and their responsiveness to B-cell receptor stimulation (Yamazaki and Kurosaki, 2003) . These results suggest that there is a PI3 kinase pathway that promotes mature B cell-specific expression of c-rel, either through c-Rel itself, PU.1, or SpiB.
The upstream pathways required for c-Rel-mediated growth, proliferation, and survival in response to mitogen stimulation have only recently started to be worked out. Based on inhibitor and knockout studies, several signaling molecules have been implicated in c-Rel function, including PI3 kinase/Akt (Andjelic et al., 2000; Grumont et al., 2002; Okkenhaug and Vanhaesebroeck, 2003; Suzuki et al., 2003) , the CARD domain proteins Bcl-10 and Carma-1 (Jun et al., 2003; Newton and Dixit, 2003; Xue et al., 2003) , and isoforms of protein kinase C (Moscat et al., 2003) . On the latter, it is interesting to note that diffuse B-cell lymphomas with poor prognosis specifically overexpress protein kinase C-b (Shipp et al., 2002) . Activation of c-Rel and B-cell proliferation/survival in response to B-cell receptor stimulation can be abolished by disruption of genes encoding the Syk (Harnett, 1996) and Bruton's tyrosine kinases (Kerner et al., 1995; Khan et al., 1995; Petro et al., 2000) , the BLNK adaptor protein (Jumaa et al., 1999; Pappu et al., 1999; Hayashi et al., 2000; Tan et al., 2001) , and phospholipase C-g2 (Wang et al., 2000; Petro and Khan, 2001) , which are all involved in the PI3 kinase pathway. On the other hand, Death Receptor 6 may be a negative regulator of c-Rel function, in that mice with this gene knocked out have increased c-Rel activity in B cells and also have increased B-cell proliferation, survival, and germinal center formation (Schmidt et al., 2003) . Not surprisingly, several c-Rel target genes in B cells are involved in growth, survival, proliferation, and antibody production (see Figure 1 and Table 1 ). 
Transformation of chicken lymphoid cells by v-Rel and c-Rel proteins
The first indication that c-Rel could be oncogenic came from the study of the avian Rev-T retrovirus, which contains v-rel as its sole gene (Gilmore, 1999 ). An understanding of Rel-induced oncogenesis in avian lymphoid cells is likely to continue to provide insights into the role that REL plays in human B-cell cancers. vRel causes a rapidly fatal B-cell lymphoma/leukemia in young chickens, and in vitro v-Rel can transform and immortalize a variety of chicken hematopoietic cell types from primary spleen, bone marrow, or bursal cultures, including B-and T-lymphoid cells, myeloid cells, erythroid cells, and dendritic cells. However, the most common targets for transformation by v-Rel are cells of the B-cell lineage, including immature and mature B cells with normal or abnormal immunoglobulin gene rearrangements. Retroviral vectors for the overexpression of chicken, mouse, and human c-Rel can also transform chicken lymphoid cells in vitro, although these normal c-Rel proteins transform less efficiently than v-Rel (Gilmore, 1999; Gilmore et al., 2001; Fan et al., 2003) . Of note, overexpression of other human family members (p50, p52, RELA, RELB) or active IKKB cannot transform chicken lymphoid cells .
v-Rel has multiple mutations that make it a more effective transforming agent than its avian progenitor cRel. The primary activating mutation in v-Rel is the deletion of C-terminal c-Rel sequences that consist of a strong transactivation domain and, thus, chicken c-Rel mutants missing these residues are more transforming than wild-type chicken c-Rel (Kamens et al., 1991; Hrdlickova´et al., 1994) . Similarly, we have recently shown that human REL can be rendered more transforming in chicken spleen cells by deletion of either one of two C-terminal transactivation subdomains (Starczynowski et al., 2003) . Moreover, the entire REL C-terminal transactivation domain can be functionally replaced in lymphoid cell transformation assays by a mutant form of the viral VP16 transactivation domain that activates at a level similar to REL, but cannot be replaced by the wild-type VP16 transactivation domain that activates approximately 10 times more potently than the REL transactivation domain (Starczynowski et al., 2003) . Taken together, these results suggest that the strength of the c-Rel transactivation domain, but not type of transactivation domain, is important for c-Rel's transforming activity. Moreover, they suggest that there is a moderate level of transactivation that is optimal for transformation of chicken lymphoid cells by c-Rel proteins. Consistent with reduced transactivation by cRel proteins being most compatible with transformation, deletions in sequences encoding C-terminal transactivation sequences frequently arise in chicken lymphoid cells transformed by viral vectors containing wild-type chicken or human c-rel (Hrdlickova´et al., 1994; Gilmore et al., 1995; Fan et al., 2003; Starczynowski et al., 2003) .
The analysis of many mutants has shown that in order for v-Rel to transform and immortalize chicken lymphoid cells in culture, v-Rel must be expressed at a high level, form homodimers, enter the nucleus (in part by escaping regulation by IkBa), bind to DNA, and activate transcription (Gilmore, 1999) . REL is also likely to transform chicken cells by activating target gene expression (Starczynowski et al., 2003) . Nevertheless, if one looks at the subcellular localization of v-Rel or REL in transformed chicken lymphoid cells by immunofluorescence, one finds that these proteins are primarily located in the cytoplasm (Gilmore, 1999; Starczynowski et al., 2003) .
How then does one resolve the discrepancy between the mutagenesis studies that indicate that v-Rel and REL must activate transcription to transform cells with the immunofluorescence data that indicate that these proteins are largely cytoplasmic in transformed cells? First, some Rel in these cells is clearly in the nucleus: by biochemical fractionation, one can readily detect some v-Rel and REL homodimers in the nuclear fractions of transformed cells, and these dimers can bind to DNA (Hrdlickova´et al., 1995a; Starczynowski et al., 2003) . Second, treatment of v-Rel-or REL-transformed spleen cells with the nuclear export inhibitor leptomycin B causes the Rel protein to accumulate in the nucleus, suggesting that these proteins are continually shuttling between the cytoplasm and the nucleus in these cells (Sachdev and Hannink, 1998; Starczynowski et al., 2003) . Third, the addition of a strong nuclear export sequence onto v-Rel reduces its ability to transform cells (Sachdev et al., 1997) , suggesting that further increasing v-Rel's cytoplasmic presence or reducing its nuclear residence impairs its transforming activity. Furthermore, shortly after infection of primary lymphoid cells with v-Rel retroviral vector, v-Rel is in the nucleus, and only after a few weeks of culture does its localization change to primarily cytoplasmic (Hrdlickova´et al., 1995b) . Taken together, these results suggest the following model for Rel-mediated transformation of chicken lymphoid cells. When an oncogenic Rel protein is initially expressed in target lymphoid cells, it is primarily in the nucleus (Hrdlickova´et al., 1995b) . However, as it progressively turns on kB site-containing target genes, including p100, p105, and IkBa, the Rel protein becomes sequestered largely in the cytoplasm (Hrdlickova´et al., 1995b). Nevertheless, even at these (2002) c-Rel and B-cell proliferation/oncogenesis TD Gilmore et al later stages, Rel complexes continue to enter the nucleus to increase (and in some cases, probably decrease) the expression of kB site target genes, and this chronic lowlevel induction of target gene expression is essential for the maintenance of the transformed state (Sachdev and Hannink, 1998; Starczynowski et al., 2003) . Consistent with this model for B-cell transformation, many v-Rel target genes in transformed chicken cells are involved in lymphoid cell growth control or survival (antiapoptosis) (reviewed in Gilmore, 1999) . Genes showing increased expression in v-Rel-transformed cells include proto-oncogenes (c-jun, c-rel), transcription factors (STAT1), cytokine receptors (IL-2Ra), growthinducing molecules (IRF-4), and antiapoptotic molecules (IAP1). Moreover, a number of genes that show increased or decreased expression in v-Rel-induced lymphoid cell tumors as compared to normal 2-week bursa have recently been identified, including several involved in adhesion, B-cell receptor signaling (through PI3 kinase), and apoptosis (Neiman et al., 2003) . It is not known which induced or repressed genes are essential for transformation by v-Rel. Because the altered expression of multiple genes probably contributes to v-Rel-induced oncogenesis, inhibition of only one or a few of these genes may not be sufficient to block oncogenesis fully.
Although all of the molecular details of v-Rel-and REL-induced transformation of avian lymphoid cells may not be identical to how misregulated REL is involved in human B-cell cancers, it is likely that the general mechanism by which Rel proteins promote avian lymphoid cell oncogenesis -by increasing the expression of cell proliferation and survival genes -is similar to what occurs in human cancers with misregulated REL. Nevertheless, it is important to point out that mutations analogous to those that enhance the oncogenicity of c-Rel proteins in avian lymphoid cells have not yet been identified in any human cancers (see below).
REL and human B-cell cancers
Aberrant, constitutively active Rel/NF-kB activity has been implicated in human cancers in several settings Karin et al., 2002) . Although p50-RelA NF-kB complexes are constitutively nuclear and active in many human tumor cell types , in most cases this activity probably contributes to the survival (i.e., antiapoptosis) of the tumor cells (Barkett and Gilmore, 1999; Baldwin, 2001) . Thus, in these settings, inhibition of NF-kB activity will likely be valuable as adjuvant therapy: that is, to sensitize tumor cells to the apoptotic effect of traditional chemo-or radiotherapeutic agents. Similarly, although genetic alterations that lead to C-terminal trunction of p100 (in the NFKB2 gene) and overexpression of the p50/p52 coactivator BCL-3 have been found in human B-cell leukemias/lymphomas Karin et al., 2002) , these proteins have not been demonstrated to have oncogenic activity in lymphoid cells in vitro or in transgenic mice.
In contrast, several lines of evidence suggest that cRel has direct and complete oncogenic activity in lymphoid cells. First, as discussed above, overexpression of human REL (but not other human Rel/NF-kB family members) can malignantly transform chicken lymphoid cells in vitro (Gilmore et al., 2001; Starczynowski et al., 2003) . Second, transgenic mice in which v-rel expression is directed by a T cell-specific promoter develop T-cell tumors, albeit with a long latency of 6-10 months (Carrasco et al., 1996) . Third, c-rel gene expression has been upregulated in B-cell lymphomas by genetic mechanisms: that is, one chicken B-cell lymphoma cell line has a retroviral integration upstream of c-rel (Kabrun et al., 1990) ; in one primary Hodgkin's lymphoma the REL gene has been translocated near the immunoglobulin light chain gene enhancer ; and the REL gene is amplified in many human lymphomas (see below).
REL gene rearrangements
REL gene rearrangements and deletions have been detected only rarely in human lymphomas. In the bestcharacterized case, the RC-K8 diffuse large B-cell lymphoma (DLBCL) cell line provides an interesting glimpse into the genetic and molecular gymnastics that some lymphoma cells may go through to ensure optimal levels of REL signaling. The RC-K8 cell line has two known mutagenic events in the REL pathway: first, due to a large deletion on chromosome 2, a chimeric REL protein (REL-NRG) is made in which the REL DNAbinding/dimerization domain is fused to sequences of unknown function (Non-Rel-Gene); and second, there are inactivating mutations in the gene encoding IkBa, such that no IkBa protein is produced (Lu et al., 1991; . The REL-NRG fusion protein can bind to kB site DNA; however, because REL-NRG lacks a functional C-terminal transactivation domain, it does not activate transcription from kB site-driven reporter genes and it cannot be inhibited by IkBa . In nuclear extracts of RC-K8 cells, one finds high levels of kB site DNA-binding complexes that exclusively contain combinations of p50, wild-type REL, and REL-NRG; furthermore, a number of known Rel/NF-kB target genes, including BCL-x, TRAF1, Bfl-1/A1, ICAM-1, and A20, show high levels of expression in RC-K8 cells . That wild-type REL activity is required for the growth of RC-K8 cells is suggested by the finding that overexpression of wild-type or the super-repressor form of IkBa kills these cells . Thus, one reasonable model for the role of REL signaling in RC-K8 cells is that the effect of constitutive REL nuclear activity, caused by the lack of IkBa protein, is reduced to a moderate and optimal oncogenic level by competition with nonactivating REL-NRG dimers. As described above for chicken lymphoid cell transformation, it seems that REL-driven oncogenesis in RC-K8 cells is maintained by a tempered level of constitutive transactivation.
c-Rel and B-cell proliferation/oncogenesis TD Gilmore et al Two additional REL gene rearrangements have recently been detected in classical Hodgkin's lymphoma tumor samples: in one case the REL gene is translocated to a position near the light chain enhancer, and in a second case there is an alteration near the 3 0 end of REL such that a C-terminally truncated REL protein is synthesized that shows strong constitutively nuclear staining .
REL gene amplifications in B-cell lymphomas REL gene amplifications have been found in a high percentage of human B-cell lymphomas (Table 2) , including B15-20% of DLBCLs Houldsworth et al., 2003) , possibly 15-20% of follicular B-cell lymphomas, and 40-50% of classical Hodgkin's lymphomas. Surprisingly, however, there are no well-characterized human B-cell lymphoma cell lines with a highly amplified REL locus, which has hindered molecular studies on the role of REL gene amplification in human B-cell lymphomas.
Despite the common amplification of the REL locus, there has been scant analysis of REL protein expression in primary human B-cell lymphomas. Namely, it is not clear whether REL gene amplification faithfully translates into increased REL protein expression. Three reports have recently used immunohistochemistry to analyse REL expression in DLBCL (Donnelly et al., 2001; Houldsworth et al., 2003) and Hodgkin's lymphoma samples. In two of the reports (Donnelly et al., 2001; Barth et al., 2003) , lymphoma samples with REL gene amplification showed increased nuclear REL staining as compared to samples without REL gene amplification. In contrast, Houldsworth et al. (2003) did not find a correlation between nuclear REL expression and REL gene amplification: that is, some DLBCL samples with a high level of REL gene amplification had less nuclear REL staining than DLBCL samples with no REL gene amplification. Nuclear REL staining has also recently been detected in five of six cases of mediastinal large B-cell lymphoma (Savage et al., 2003) .
Instinctively, one might conclude that only lymphomas with nuclear REL staining have REL-driven oncogenic activity. However, it is important to remember that immunocytochemistry provides only a static picture of REL. As discussed above, v-Rel and REL in transformed chicken spleen cells also appear to be primarily cytoplasmic proteins by immunofluorescence, and yet the evidence is quite convincing that these oncogenic proteins are continually entering the nucleus to drive the gene transcription that causes transformation and immortalization of these cells. Thus, one cannot assume that cytoplasmic REL staining of lymphoma samples mandates inactive REL complexes. On the other hand, in that c-Rel complexes are normally in the nucleus of mature B cells, one cannot determine by immunolocalization whether nuclear REL staining in specific human B-cell lymphomas is driving malignancy or is simply a marker for the developmental stage of the given tumor.
Does REL gene amplification define a molecularly distinct subclass of DLBCL?
One cannot discuss the molecular basis of human B-cell lymphomas without addressing the pioneering work of Standt and colleagues on the molecular profiling and categorizing of DLBCLs (reviewed in Shaffer et al., 2002) , which may also have relevance to REL-induced oncogenesis. Based on cDNA microarray expression patterns, Staudt's group has divided otherwise clinically homogeneous DLBCLs into three sub-types: ABC type (with expression patterns similar to Activated B cells), GCB type (with patterns similar to Germinal Center B cells), and type III (with patterns distinct from the first two) (Alizadeh et al., 2000; Rosenwald et al., 2002) . The ABC and GCB DLBCLs have been characterized in most detail. The ABC DLBCL subtype, which was reported to have a poorer clinical prognosis by Rosenwald et al. (2002) , has a group of NF-kB target genes that have elevated expression. Paradoxically, these 'NF-kB' target genes are not highly expressed in the GCB subtype, even though REL gene amplifications were exclusively found in B15% of the GCB DLBCLs . By electrophoretic mobility shift assays, two ABC-like cell lines were reported to have more constitutively nuclear kB site binding activity than two GCB-type cell lines, and the proliferation of the ABC cell lines was inhibited by introduction of a vector encoding the IkBa super-repressor, whereas proliferation of GCB cell lines was not inhibited by the IkBa super-repressor vector (Davis et al., 2001) . Taken together, these results led to the suggestion that constitutive activation of the Rel/NF-kB pathway contributes to the sustained oncogenicity of the ABClike DLBCLs but not the GCB-like DLBCLs (Davis et al., 2001) .
As provocative as the results of Staudt's group may be, their experiments have some loose ends. First, a recent analysis of a new panel of DLBCLs using the Staudt cDNA expression criteria found REL gene amplifications in about 20% of the samples in all three molecular subtypes, and did not find that the ABC subtype had a poorer clinical outcome (Houldsworth et al., 2003) . Second, we believe that it is an exaggeration to say that the nuclear kB site binding activity in the GCB-like cell lines that Staudt's group has characterized as having 'low' nuclear NF-kB activity is really all that low. For example, as shown in Figure 2 , the amount of active DNA-binding activity in the SUDHL-4 GCB-like cell line ('low NF-kB activity') is similar to that in extracts from TNFa-stimulated 3T3 cells, which are commonly regarded as having 'high' or induced nuclear kB site binding activity. However, the RC-K8 DLBCL cell line, which has no IkBa, has significantly more nuclear c-Rel DNA-binding activity than either SUDHL-4 cells or TNFa-stimulated mouse fibroblasts (see Figure 2 ; . Third, the active Rel/NF-kB family proteins that were found in nuclear extracts of ABC versus GCB cell lines are largely different: whereas the ABC lines had generally p50-RelA, the GCB cell lines had REL-containing c-Rel and B-cell proliferation/oncogenesis TD Gilmore et al complexes (Davis et al., 2001; Liang et al., 2003) . The significance and activity of different nuclear kB site DNA-binding complexes in the two DLBCL subtypes is not clear. In addition, although the GCB-like SUDHL-4 cells were not killed by expression of the IkBa superrepressor (Davis et al., 2001) , we have recently shown that we can readily kill GCB-like SUDHL-4 cells with a synthetic NF-kB signaling inhibitor that correspondingly reduces the REL DNA-binding complexes (Liang et al., 2003) . Furthermore, IkBa has recently been shown to interact with tumor suppressor p53 (Chang, 2002; Zhou et al., 2003) and cell-cycle kinase CDK4 , suggesting that overexpression of IkBa or the IkBa super-repressor may have effects in addition to inhibition of NF-kB. How does one explain the apparent paradox of the presence of REL gene amplifications in a relatively high percentage (15%) of the DLBCL subtype (GCB) that does not contain elevated NF-kB target gene expression and that is not killed by overexpression of the IkBa super-repressor ? First, REL gene amplifications may have nothing to do with DLBCL oncogenesis (for example, REL amplifications may be a phenotype of this type of malignant cell or Hodgkin's 2/2 (100%) Martin-Subero et al. (2003) Primary mediastinal 2/26 (8%) Joos et al. (1996) Primary mediastinal 2/40 (5%) Palanisamy et al. (2002) Aggressive B cell 3/61 (5%) Werner et al. (1997) Extranodal marginal zone (MALT type) 2/18 (11%) Barth et al. (2001) Cutaneous CD30+ anaplastic large cell lymphoma 6/8 (75%) Mao et al. (2003) GI, gastrointestinal; GCB, germinal center B cell; NS, nodular sclerosis c-Rel and B-cell proliferation/oncogenesis TD Gilmore et al amplification of genes near REL may be important for malignancy (see Discussion below of BCL11a)). Second, as suggested by Shaffer et al. (2002) , increased REL activity provided by REL gene amplification may not be relevant to final stage growth of GCB DLBCLs, but may be important at any earlier stage. Third, REL gene amplification may be important for GCB-like DLBCL cell growth in vivo but not in vitro. Indeed, it is important to note that the GCB cell lines that Davis et al. (2001) analysed for in vitro growth inhibition by the IkBa super-repressor were not those that contained REL gene amplifications. GCB DLBCLs with REL gene amplifications (and possibly REL overexpression) may respond differently to overexpression of IkBa than those without REL gene amplification/overexpression. Thus, we believe that it is unresolved whether REL/NF-kB contributes to the malignant state in only a subset of DLBCLs.
Genes that might cooperate with deregulated REL in B-cell oncogenesis Survival, developmental, or proliferation genes may cooperate with REL in B-cell tumorigenesis. Two lines of evidence point to the well-known antiapoptotic gene BCL-2 as one such REL-cooperating gene. First, BCL2 is rearranged in a high percentage of GCB-like DLBCLs, which constitute the same subclass of DLBCLs in which REL gene amplifications are exclusively found . Second, coexpression of Bcl-2 can enhance the transforming activity of weakly transforming mutants of v-Rel and of human REL in chicken lymphoid cells (White and Gilmore, 1996; Gilmore et al., 2001; Rayet et al., 2003) . A second candidate gene for cooperating with REL is the BCL11a (aka Evi9) gene, which is located quite near to REL at chromosome 2p13 and is frequently coamplified with REL in B-cell lymphomas (Satterwhite et al., 2001) . Indeed, it is not clear whether the criminal gene in these amplifications is REL, BCL11a, both, or neither. In addition, the BCL11a gene is translocated into the Ig heavy chain locus in a subset of B-cell chronic lymphocytic leukemias , and is activated by retroviral insertions in some mouse myeloid leukemias Suzuki et al., 2002) . BCL11a can transform mouse 3T3 cells , but has not been shown to transform lymphoid cells. Bcl11a knockout mice die shortly after birth, and embryos from these mice have no B cells, due to a defect in the development of pre-pro-B cells from a lymphoid precursor cell . BCL11a encodes a zinc-finger Kruppel-like transcription repressor protein; however, its target genes are not known. It is tempting to speculate that the balance between RELinduced gene activation and BCL11a-directed gene repression cooperates in certain B-cell lymphomas that have 2p13 amplicons, and certainly studies are warranted to determine whether REL and BCL11a can cooperate in B-cell oncogenesis in either avian or mouse systems.
The genes encoding interferon regulatory factor 4, a B cell-specific transcriptional repressor, and the protooncogene c-myc are both transcriptional targets of c-Rel and could also be REL cooperating genes in B-cell lymphomagenesis. The IRF-4 gene is upregulated by c-Rel in mitogen-stimulated B cells (Grumont and Gerondakis, 2000) and IRF4À/À B cells proliferate poorly in response to mitogens (Mittrucker et al., 1997) . Furthermore, the IRF4 gene is translocated into the immunoglobulin heavy chain locus in some human myelomas (Iida et al., 1997) and B-cell lymphomas (Tamura et al., 2001) , and is highly expressed in many DLBCLs (Tsuboi et al., 2000) . Similarly, alterations in c-myc gene structure and activity occur in many animal and human B-cell cancers (Popescu and Zimonjic, 2002) .
Proliferative activities of Rel that may not involve direct regulation of transcription
The discussion above has made the tacit assumption that the proliferative and survival effects of c-Rel in B cells are all manifested by direct effects of c-Rel on gene transcription. However, it is important to acknowledge that c-Rel may have effects that do not involve direct DNA binding and gene activation. have shown that C-terminal sequences of REL can bind to cyclin E and Cdk2 complexes, suggesting that c-Rel could have nontranscriptional effects on cell-cycle regulatory proteins. Mice in which sequences encoding the C-terminal transactivation domain of c-Rel have been knocked out show B-cell hyperplasia (Carrasco et al., 1998) . Finally, v-Rel can stimulate replication of viral DNA (Ishikawa et al., 1993) .
Conclusions and perspectives
As outlined in this review, there is reason to believe that enhanced REL activity plays a role in a large number of human B-cell lymphomas. Nevertheless, the involvement of REL in human lymphoid cell cancers is Figure 2 kB site DNA-binding activity in human diffuse B-cell lymphoma cell lines. Cell extracts from the indicated cell lines were analysed by an electrophoretic mobility shift assay using a radiolabeled kB site probe as described (Liang et al., 2003) . Mouse 3T3 cells plus or minus tumor necrosis factor; SUDHL-4 lymphoma cells (NF-kB is mainly p50-REL; Liang et al., 2003) ; RC-K8 lymphoma cells (NF-kB is comprised of complexes containing p50, REL, and REL-NRG; c-Rel and B-cell proliferation/oncogenesis TD Gilmore et al unproven in that: (1) the REL gene amplifications seen in human diffuse B-cell lymphomas and Hodgkin's lymphomas still provide only circumstantial evidence that they are involved in the generation or maintenance of these cancers; (2) there is still only a single model system (the avian lymphoid cell system) in which human REL has clearly been shown to be oncogenic; and (3) there are no specific inhibitors of REL that one can use to test directly whether amplified or overexpressed REL is required for B-cell tumor growth.
The missing mouse model for REL-induced B-cell oncogenesis
In spite of the acute transforming activity of v-Rel and chicken, mouse and human c-Rel in primary chicken spleen cells, there have been no reports of Rel-mediated transformation of mouse B lymphocytes. Indeed, early reports demonstrated that v-Rel expression directed by a retroviral vector was toxic in primary mouse bone marrow cells (Schwartz and Witte, 1988) . Despite a number of attempts, we have not been able to transform primary mouse bone marrow or spleen cells by infection with retroviral vectors for the expression of v-Rel or human REL. Similarly, v-Rel cannot convert the pro-B cell line BaF3 to growth factor independence . Moreover, there have been no reports of transgenic mice that are capable of sustained B cellspecific expression of wild-type c-rel. Finally, c-rel was not identified as a site for retroviral integration in mouse lymphomas in extensive screens for gene targets of insertional mutagenesis in mouse lymphomas (Lund et al., 2002; Suzuki et al., 2002) . How then to reconcile the acute oncogenicity of Rel proteins in avian B cells and the frequent amplification of REL in human B-cell lymphomas with the apparent inability of Rel proteins to transform murine B cells? There are three likely explanations. First, it may simply be that for technical reasons, the oncogenicity of c-Rel proteins has not been demonstrated in mouse B cells: that is, that the Rel proteins need to be expressed under specific conditions in vitro or in vivo for their oncogenicity to be apparent. For example, sustained expression of c-Rel might be required at a specific stage of B-cell development (e.g., only at the mature B-cell stage) for transgenic mice to develop B-cell lymphomas. Second, it may be that avian and human B cells are susceptible to Rel-induced transformation, whereas mouse B cells are not. Indeed, with respect to expression of some tumor suppressor proteins and telomerase, chicken cells and human cells are similar to one another and distinct from mouse cells (Forsyth et al., 2002; Kim et al., 2002) . Third, avian lymphoid cells may be susceptible to singlestep transformation by Rel proteins (even from diverse species), while mammalian B cells require additional events. For example, chickens appear to lack the Ink4a retinoblastoma inhibitor protein and a fully functional Arf tumor suppressor . Mouse cells are not entirely refractory to transformation by Rel proteins in that v-Rel and mouse c-Rel can induce tumors in transgenic mice in T cells and mammary cells, respectively, albeit with an extremely long latency in both cases (Carrasco et al., 1996; Romieu-Mourez et al., 2003) .
Thus, the development of mammalian cell and animal systems for the study of REL-induced B-cell lymphomagenesis represents an important goal. In the mouse, this may entail the coexpression of REL with other Bcell proliferation or survival proteins in vitro in appropriate cell types or the expression of REL in transgenic mice at a specific stage of B-cell development or in a suitable genetic background. In human cells, the overexpression of REL (and perhaps cooperating proteins) in primary human lymphocytes may result in the establishment of long-term liquid cell cultures (as occurs with Epstein-Barr virus). In addition, the establishment of B-cell lymphoma cell lines from primary human tumors with amplified REL will be useful for identifying REL target genes involved in oncogenesis and for anti-REL therapy efforts.
Anti-REL therapy
REL may be a particularly suitable therapeutic transcription factor target for several reasons. First, gene knockouts of c-rel do not affect development or viability in mice, and the activity of c-Rel appears to be primarily required for the proliferation and survival of activated mature B cells. Thus, anti-REL therapeutics may be generally tolerated. Second, REL gene amplifications are now being identified with reasonable frequency in a variety of somewhat common and therapeutically accessible tumor types, including Hodgkin's and nonHodgkin's B-cell lymphomas. Third, the structure of the DNA-binding domain of c-Rel has been solved (Huang et al., 2001) . Fourth, some Hodgkin's tumor cells and DLBCLs have inactivating mutations in IkB genes (Wood et al., 1997; Cabannes et al., 1999; Krappmann et al., 1999; Jungnickel et al., 2002; Emmerich et al., 2003) , and thus the Rel pathway is activated downstream of IKK; as such, some REL-driven lymphoid cell cancers may be refractory to IKK inhibitors or may develop resistance to IKK inhibitors through mutations that inactivate IkBa. Therefore, direct inhibitors of REL, rather than inhibitors of upstream Rel/NF-kB signaling molecules, are likely to prove to be superior therapeutics for many Hodgkin's and DLBCLs. Nevertheless, how one might target c-Rel activity is not obvious. However, compounds that either specifically affect REL dimerization (with itself or p50) or REL's interaction with downstream activators (e.g., through protein-protein interactions mediated by the unique sequences of the REL transactivation domain) may provide safe and effective therapies for a variety of human B-cell lymphomas.
